Complete Story
03/18/2026
Product Updates
Bristol Myers Squibb Announces Positive Phase 3 Results from the SUCCESSOR-2 Study of Oral Mezigdomide in Relapsed or Refractory Multiple Myeloma
More InfoReport Broken Links
Have you encountered a problem with a URL (link) on this page not working or displaying an error message? Help us fix it!
